Tianjin Tianyao Pharmaceuticals Co Ltd (SHG:600488) — Market Cap & Net Worth
Market Cap & Net Worth: Tianjin Tianyao Pharmaceuticals Co Ltd (600488)
Tianjin Tianyao Pharmaceuticals Co Ltd (SHG:600488) has a market capitalization of $910.73 Million (CN¥6.22 Billion) as of May 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #9525 globally and #2643 in its home market, demonstrating a -13.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Tianyao Pharmaceuticals Co Ltd's stock price CN¥5.70 by its total outstanding shares 1091886680 (1.09 Billion). Analyse 600488 cash flow metrics to see how efficiently the company converts income to cash.
Tianjin Tianyao Pharmaceuticals Co Ltd Market Cap History: 2015 to 2026
Tianjin Tianyao Pharmaceuticals Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.13 Billion to $910.73 Million (-0.79% CAGR).
Tianjin Tianyao Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Tianyao Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Tianjin Tianyao Pharmaceuticals Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.08x
Tianjin Tianyao Pharmaceuticals Co Ltd's market cap is 5.08 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.13 Billion | $1.40 Billion | $78.72 Million | 0.80x | 14.30x |
| 2016 | $952.58 Million | $1.21 Billion | $63.81 Million | 0.79x | 14.93x |
| 2017 | $742.21 Million | $1.97 Billion | $129.81 Million | 0.38x | 5.72x |
| 2018 | $579.00 Million | $2.43 Billion | $153.45 Million | 0.24x | 3.77x |
| 2019 | $654.00 Million | $2.92 Billion | $145.28 Million | 0.22x | 4.50x |
| 2020 | $782.00 Million | $3.12 Billion | $80.58 Million | 0.25x | 9.71x |
| 2021 | $729.61 Million | $3.75 Billion | $108.67 Million | 0.19x | 6.71x |
| 2022 | $703.36 Million | $3.69 Billion | $18.44 Million | 0.19x | 38.15x |
| 2023 | $782.91 Million | $3.78 Billion | $117.05 Million | 0.21x | 6.69x |
| 2024 | $677.46 Million | $3.22 Billion | $133.45 Million | 0.21x | 5.08x |
Competitor Companies of 600488 by Market Capitalization
Companies near Tianjin Tianyao Pharmaceuticals Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Tianjin Tianyao Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Tianjin Tianyao Pharmaceuticals Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Tianjin Tianyao Pharmaceuticals Co Ltd's market cap moved from $1.13 Billion to $ 910.73 Million, with a yearly change of -0.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥910.73 Million | +39.36% |
| 2025 | CN¥653.49 Million | -3.54% |
| 2024 | CN¥677.46 Million | -13.47% |
| 2023 | CN¥782.91 Million | +11.31% |
| 2022 | CN¥703.36 Million | -3.60% |
| 2021 | CN¥729.61 Million | -6.70% |
| 2020 | CN¥782.00 Million | +19.57% |
| 2019 | CN¥654.00 Million | +12.95% |
| 2018 | CN¥579.00 Million | -21.99% |
| 2017 | CN¥742.21 Million | -22.08% |
| 2016 | CN¥952.58 Million | -15.37% |
| 2015 | CN¥1.13 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Tianjin Tianyao Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $910.73 Million USD |
| MoneyControl | $910.73 Million USD |
| MarketWatch | $910.73 Million USD |
| marketcap.company | $910.73 Million USD |
| Reuters | $910.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more